Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp. develops cancer screening and diagnostic tests used before, during, and after a cancer diagnosis. Company news centers on established products such as Cologuard and Oncotype DX, as well as newer diagnostics including Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease and recurrence monitoring.
Recurring updates include clinical data presentations in breast cancer and multi-cancer detection, policy and coverage developments for diagnostic testing, precision oncology product milestones, material agreements, shareholder voting matters, capital-structure disclosures, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exact Sciences (NASDAQ: EXAS) announced advancements in cancer detection at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The company emphasizes the efficiency of advanced imaging after a positive multi-cancer early detection (MCED) test for identifying tumor locations. Preliminary findings suggest potential for molecular residual disease (MRD) detection technologies in monitoring cancer recurrence post-therapy. Key presentations include data showing fewer diagnostic procedures needed with advanced imaging compared to molecular testing, and promising results from tumor-informed MRD methodologies in distinguishing cancer samples. The developments could enhance early detection strategies and improve treatment decision-making for patients.
Exact Sciences Corp. (NASDAQ: EXAS) announced it will release its Q1 2023 financial results on May 9, 2023, after U.S. financial markets close. A conference call and webcast will follow at 5 p.m. ET to discuss the results and business developments. Exact Sciences, a leader in cancer screening and diagnostics, is known for its innovative products like Cologuard® and Oncotype®. The company continues to invest in its product pipeline to enhance patient care before and during cancer treatment.
For details, join the webcast at www.exactsciences.com or dial in at 888-330-2384 (domestic) and +1 240-789-2701 (international).
Exact Sciences Corp. (Nasdaq: EXAS) announced a transaction on February 23, 2023, involving the exchange of $500 million in new 2.00% Convertible Senior Notes due March 1, 2030, for existing convertible notes totaling approximately $384 million and $138 million in cash. The transaction is set to close on March 1, 2023. The new notes will have a semi-annual interest payment structure and can be converted into shares of common stock or cash, beginning September 1, 2023. The initial conversion price is about $80.83 per share, indicating a 25% premium over the previous closing price of $64.66.
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer screening, announced its participation in key investor conferences in March 2023. The company will host fireside chats at:
- Citi's Healthcare Services Conference on March 1 at 2:45 p.m. ET in New York.
- Cowen Health Care Conference on March 6 at 10:30 a.m. ET in Boston.
- Raymond James Institutional Investors Conference on March 7 at 4:00 p.m. ET in Orlando.
Investors can access webcasts of the presentations on the Exact Sciences website. The company focuses on innovative cancer diagnostic solutions and is dedicated to improving patient outcomes.
Exact Sciences Corp. (Nasdaq: EXAS) reported a record fourth-quarter revenue of $553 million, marking a 17% increase, and $2,084 million for the full year 2022, an 18% increase. Excluding COVID-19 testing, fourth-quarter revenue grew by 28%. The company anticipates 2023 revenue between $2,265-$2,315 million. Notably, Screening revenue reached $404 million in Q4 2022, a 45% increase, while Precision Oncology revenue dropped 4% to $143 million. The net loss for the quarter was $127.7 million or $0.72 per share. Despite the losses, Exact Sciences reaffirmed its position with strong partnerships and innovative testing solutions.